logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
4/24/2018 7:02:35 AM Alnylam Reports New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At AAN 2018 Annual Meeting
4/23/2018 7:02:22 AM Alnylam Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-TTRsc02
4/20/2018 2:13:35 PM Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals
3/28/2018 7:03:05 AM Alnylam Presents New Clinical Results From The APOLLO Phase 3 Study Of Patisiran
3/26/2018 7:01:47 AM Alnylam Gets EMA PRIME Designation For Lumasiran For Primary Hyperoxaluria Type 1 (PH1)
3/14/2018 7:01:07 AM Alnylam To Report New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th ISA
3/12/2018 7:02:08 AM Alnylam Retains Global Rights To Lumasiran; Plans To Accelerate Development With Phase 3 Start In Late 2018